Method for determining the release rate of aripiprazole long-acting dry suspension injection

Through the combination of dissolution bottle method and dialysis bag, the problem of overestimation of dissolution volume and drug loss in the long-acting dry-suspended injection release determination is solved, achieving more accurate in vivo release simulation and cost reduction, providing Efficient and sensitive release detection.

CN115184496BActive Publication Date: 2024-11-19YANTAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210815636.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-11
Publication Date
2024-11-19
Estimated Expiration
2042-07-11

AI Technical Summary

Technical Problem

The prior art has problems with overestimating the dissolution volume and loss of drug particles when determining the release degree of aripiprazole long-acting dry-suspended injection, and the cost is high. The traditional method has a large sample loading volume, making it difficult to accurately reflect the release in vivo. Behavior.

Method used

Use dissolution bottle method to combine dialysis bags, add Tween 80 and SDS to PBS buffer at 0.1 mol/L, pH 7.4, adjust the pH to 6.4, and prepare release media A and B. The injection site reservoir was simulated through the dialysis bag, and combined with High performance liquid chromatography system determines peak area and calculates the release degree.

Benefits of technology

This method can more accurately simulate in vivo release behavior, reduce drug loss, reduce costs, provide reliable and highly sensitive release detection, is suitable for insoluble preparations, and achieves a rapid release curve under accelerated conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115184496B_ABST
    Figure CN115184496B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for determining the release of aripiprazole long-acting dry suspension injection, and belongs to the field of drug detection technology. The method comprises the following steps: preparing release medium A and release medium B, adding release medium A and drug to a dialysis bag, adding release medium B to a dissolution bottle, placing the dialysis bag in the dissolution bottle, placing the dissolution bottle in a constant temperature water bath shaker at 37°C to 40°C, sampling from the dissolution bottle at different time points, performing HPLC detection, and calculating the release of the drug by the ratio of the cumulative release amount of the drug to the total amount of the drug. The benefits of the present invention are: it can better simulate the process of the drug in the body, can well reflect the release behavior of the drug in the body, has good in vitro and in vivo correlation, and is more suitable for the determination of poorly soluble preparations; greatly reduces the amount of drug used; simple operation, easy to obtain materials, and has good specificity, sensitivity, linearity, repeatability, accuracy, stability and release reproducibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for measuring the release rate of a drug, in particular to a method for measuring the release rate of an aripiprazole long-acting dry suspension injection, and belongs to the technical field of drug detection. Background Art

[0002] Aripiprazole is a dihydroquinolone antipsychotic drug that partially stimulates dopamine-2 (D2) receptors and 5-hydroxytryptamine 1A (5-HT1A) receptors, and completely antagonizes 5-hydroxytryptamine 2A (5-HT2A) receptors. This unique pharmacological property enables aripiprazole to enhance neurotransmission function when dopaminergic neurotransmission levels are reduced, and reduce neurotransmission function when dopaminergic neurotransmission levels are hyperactive. Therefore, aripiprazole is also known as the first "dopamine system stabilizer". Aripiprazole can not only improve negative cognition and negative symptoms of depressed patients, but also improve positive mental symptoms, and has good safety and tolerability. It is widely used in the treatment of schizophrenia, bipolar disorder, major depression, autism and childhood autism.

[0003] Aripiprazole long-acting dry suspension injection (trade name: Abilify Maintena), a long-acting preparation of aripiprazole commonly used in clinical practice, is a once-monthly intramuscular injection preparation. This preparation not only significantly prolongs the drug's duration of action, maintains long-term drug exposure in the body and improves the drug's bioavailability, but also significantly reduces the patient's frequency of medication and significantly improves compliance.

[0004] Like ordinary dosage forms, aripiprazole long-acting dry suspension injection needs to reach a certain blood drug concentration in the body before it can exert its efficacy, so drug release and absorption are key factors affecting the efficacy in the body. At present, the method for determining the release rate of aripiprazole long-acting dry suspension injection is mainly the dissolution method in the registration standard for imported drugs - the dissolution instrument paddle method. Take this product and determine it according to the dissolution and release rate determination method (Chinese Pharmacopoeia 2015 Edition Part Four General Rules 0931 Second Method). The specific operation of the determination process is as follows:

[0005] The lyophilized powder was mixed with sterile water for injection, and after vigorous shaking for 20 seconds, an injection needle (22G, 1.5 inches) was installed on the syringe, and 6 mL (400 mg specification) was discharged and placed in a dissolution cup. 894 mL (400 mg specification) of 0.25% sodium dodecyl sulfate (Sigma-Aldrich, specification L6026, purity ≥99.0%) solution was used as the dissolution medium, and the rotation speed was 50 rpm. The operation was carried out in accordance with the law, and 10 mL of the solution was taken after 15 min, 2 h, and 8 h, and the dissolution medium of the same temperature and the same volume was immediately supplemented, filtered, and the filtrate was taken as the test solution; about 50 mg of aripiprazole reference substance was accurately weighed, placed in a 1000 mL volumetric flask, 100 mL of ethanol was added to dissolve it, and it was diluted to the scale with 1% sodium dodecyl sulfate solution as the reference substance solution. Take the above two solutions, measure the absorbance of the two solutions at 252nm and 325nm wavelengths according to the UV-Vis spectrophotometry (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0401), and calculate the release of each injection by the difference. The release of this product at 15min, 2h, and 8h is 32% to 52%, 55 to 75%, and more than 85% of the labeled amount, respectively, which should meet the requirements.

[0006] Since aripiprazole long-acting dry suspension injection forms a drug reservoir at the injection site after being administered by intramuscular injection, and then produces a long-acting sustained-release effect through slow dissolution, release and absorption, and aripiprazole is a BCS class II compound and a poorly soluble drug, the use of traditional release methods to determine the release of aripiprazole long-acting dry suspension injection will have the following problems:

[0007] (1) Because traditional release methods use large volumes of release media, the dissolution volume of aripiprazole long-acting dry suspension injection after injection may be overestimated;

[0008] (2) Since the aripiprazole long-acting dry suspension injection (lyophilized powder) is suspended in the release medium of the dissolution cup in the traditional release method, the suspended drug particles may also be taken out during the sampling operation, resulting in loss, which may lead to large errors in the dissolution determination.

[0009] In addition, due to the high requirements of the preparation of aripiprazole long-acting dry suspension injection, the production cost is high, but the release rate determination method of the dissolution apparatus paddle method requires a large sample volume, so the cost of release testing is relatively high. Summary of the invention

[0010] To address the deficiencies of the prior art, the present invention aims to provide a reliable release method that can release over a long period of time and can better simulate the in vivo process, and can also obtain a rapid release curve by accelerating the release. The method is economical and practical and can meet the requirements of inspection and quality control for detecting the release rate of aripiprazole long-acting dry suspension injection.

[0011] In order to achieve the above object, the present invention adopts the following technical solution:

[0012] A method for determining the release rate of aripiprazole long-acting dry suspension injection, characterized in that it comprises the following steps:

[0013] Step 1: Add Tween 80 to 0.1 mol / L PBS buffer at pH 7.4, the concentration of Tween 80 is 0.2 ml / L, the pH value of the mixed solution is adjusted to 6.4, and ultrasonic degassing is performed to prepare release medium A;

[0014] Step 2: Weigh SDS and sodium azide, dissolve them in a small amount of ultrapure water, mix them and make up to volume. The concentration of SDS is 2.5 g / L, and the concentration of sodium azide is 1.0 g / L. Degas by ultrasonication to prepare release medium B.

[0015] Step 3: Add 1 mL of release medium A and 3.5 mg of aripiprazole long-acting dry suspension injection lyophilized powder to the dialysis bag, tie the dialysis bag tightly, add 45 mL of release medium B to the dissolution bottle, place the dialysis bag in the dissolution bottle, place the dissolution bottle in a constant temperature water bath shaker maintained at 37°C to 40°C, make three parallels, take samples from the dissolution bottle at different time points, and add an equal amount of fresh release medium B to the dissolution bottle;

[0016] Step 4: Pass the samples obtained at different sampling time points through a 0.22 μm filter membrane to obtain a test solution, and use a high performance liquid chromatography system to determine the peak area of ​​the test solution;

[0017] Step 5: The release amount at each time point is calculated by the peak area using the external standard method, and the release rate of aripiprazole long-acting dry suspension injection is calculated by the ratio of the cumulative release amount of the drug to the total amount of the drug.

[0018] Preferably, the method further comprises the step of pre-treating the dialysis bag, specifically: cutting the dialysis bag into a suitable length, first soaking it in ultrapure water for 1 hour, then soaking it in an ethanol-water solution for 20 minutes, wherein the volume ratio of ethanol to water is 2:8, and finally storing it at 2°C to 8°C for future use.

[0019] Preferably, in Step 3, the dialysis bag is a 8kD to 14kD regenerated cellulose dialysis bag.

[0020] Preferably, in Step 3, 2 mL is sampled each time and passed through a 0.22 μm filter.

[0021] Preferably, in Step 4, the filter membrane is a polyethersulfone filter membrane, and more than 0.5 mL of the filtrate is discarded to obtain the test solution.

[0022] Preferably, in Step 4, the chromatographic conditions of the high performance liquid chromatography system are as follows:

[0023] Chromatographic column: Agilent ZORBAX SB-C18, 4.6×150 mm, 5 μm;

[0024] Column temperature: 35°C;

[0025] Flow rate: 1.0 mL / min;

[0026] Detection wavelength: 257nm;

[0027] Injection volume: 20 μL;

[0028] Mobile phase: 150 mL of 20 mmol / L potassium dihydrogen phosphate solution was mixed with 350 mL of acetonitrile, the pH value was adjusted to 7.4 with phosphoric acid, and ultrasonic degassing was performed for 20 min.

[0029] The present invention is beneficial in that:

[0030] (1) The method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention specifically uses the dissolution bottle method combined with a dialysis bag. Compared with the traditional release method, it can better simulate the process of the drug in the body, can well reflect the release behavior of the drug in the body, has a good in vitro and in vivo correlation, and is more suitable for the determination of poorly soluble preparations;

[0031] (2) Compared with the conventional release method, the method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention uses a dialysis bag to load the lyophilized powder of aripiprazole long-acting dry suspension injection, which can avoid sample loss during sampling operation and greatly reduce the amount of drug used;

[0032] (3) The method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention is simple to operate, the materials are readily available, and it has good specificity, sensitivity, linearity, repeatability, accuracy, stability and release reproducibility, and provides a reliable method for determining the release rate of aripiprazole long-acting dry suspension injection lyophilized powder;

[0033] (4) The method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention can achieve rapid and complete release of the lyophilized powder of aripiprazole long-acting dry suspension injection under temperature acceleration conditions, and suitable temperature conditions can be selected according to specific experimental requirements, thereby providing a reliable and diversified option for determining the release rate of aripiprazole long-acting dry suspension injection. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 are HPLC graphs of the test solution and the blank release medium, wherein (a) is the HPLC graph of the test solution, and (b) is the HPLC graph of the blank release medium;

[0035] Figure 2 It is the standard curve of the linear range of aripiprazole release determination;

[0036] Figure 3 It is the time-release curve of the test product under different release medium A conditions;

[0037] Figure 4 It is the time-release curve of the test product at 37℃, 38.5℃ and 40℃;

[0038] Figure 5 is a correlation diagram of the release at 37°C and under accelerated conditions (38.5°C and 40°C), wherein (a) is a correlation diagram of the release at 37°C and 38.5°C, and (b) is a correlation diagram of the release at 37°C and 40°C;

[0039] Figure 6 The present invention discloses a correlation diagram between the release curve of a test sample obtained by the method for determining the release of aripiprazole long-acting dry suspension injection provided by the present invention and the in vivo drug release, wherein (a) is a linear correlation diagram of the cumulative drug release curve in an in vitro experiment (37° C.) and the cumulative drug release (absorbance) in vivo after intramuscular injection in rabbits, and (b) is a linear correlation diagram of the cumulative drug release in an in vitro experiment (37° C.) and the cumulative drug release (absorbance) in vivo after intramuscular injection in rabbits. DETAILED DESCRIPTION

[0040] The method for measuring the release rate of aripiprazole long-acting dry suspension injection provided by the present invention specifically uses a dissolution bottle method in combination with a dialysis bag, and loads different release media in the dialysis bag and the dissolution bottle, respectively, wherein the release medium loaded in the dialysis bag is recorded as release medium A (simulating the tissue fluid around the injection site reservoir), and the release medium loaded in the dissolution bottle is recorded as release medium B (simulating systemic blood). During the release process, the lyophilized powder of the aripiprazole long-acting dry suspension injection is first dissolved by the release medium A in the dialysis bag, and the dissolved drug passes through the dialysis bag into the dissolution bottle, and then is sampled and measured in the release medium B.

[0041] In order to better understand and illustrate the present invention, the present invention is further described in detail below in conjunction with specific embodiments. The given embodiments are only for illustrating the present invention, rather than for limiting the scope of the present invention.

[0042] 1. Determination of the release rate of aripiprazole long-acting dry suspension injection

[0043] Example 1

[0044] 1. Dialysis bag pretreatment

[0045] Select 8kD to 14kD regenerated cellulose dialysis bags. Regenerated cellulose dialysis bags can withstand temperatures up to 60°C, which can meet the needs of accelerated experiments selected according to different experimental requirements.

[0046] Cut the dialysis bag to an appropriate length (about 8 cm), soak it in ultrapure water for 1 hour, then soak it in ethanol-water (V:V=2:8) solution for 20 minutes, and finally store it at 2°C to 8°C for later use.

[0047] Before use, rinse the dialysis bag twice in ultrapure water, then soak it in ultrapure water for 20 minutes, tie one end of the dialysis bag tightly, and finally add some clean water and gently squeeze it to observe whether the dialysis bag leaks. It can be used only after confirming that the dialysis bag is not leaking.

[0048] In the present invention, the dialysis bag is used to simulate the in vivo process of aripiprazole long-acting dry suspension injection forming a reservoir at the injection site. After the dialysis bag is pre-treated as above, the possibility of adsorbing drug powder can be reduced.

[0049] 2. Preparation of release medium A and release medium B

[0050] (1) Preparation of release medium A

[0051] Release medium A is 0.1 mol / L PBS buffer solution with Tween 80 (surfactant) added thereto, and the concentration of Tween 80 is 0.2 ml / L (volume fraction is 0.02%).

[0052] The method for preparing release medium A is as follows:

[0053] First, 1 L of 0.1 mol / L PBS buffer (pH = 7.4) was prepared, and then 0.2 ml of Tween 80 was added to the PBS buffer, and the concentration of Tween 80 was 0.2 ml / L (volume fraction was 0.02%). Then, the pH value of the mixed solution was adjusted to 6.4 with a phosphoric acid solution, and finally ultrasonic degassing was performed for 20 minutes to prepare release medium A.

[0054] (2) Preparation of release medium B

[0055] Release medium B is a 2.5 g / L sodium dodecyl sulfate (SDS) aqueous solution in which sodium azide (preservative) is added, and the concentration of sodium azide is 1.0 g / L.

[0056] The method for preparing release medium B is as follows:

[0057] First, 2.5 g of SDS and 1.0 g of sodium azide were weighed, then dissolved with a small amount of ultrapure water, mixed and fixed to 1 L, and finally ultrasonically degassed for 20 min to prepare release medium B.

[0058] 3. Simulate the release process

[0059] Add 1 mL of release medium A and 3.5 mg of aripiprazole long-acting dry suspension injection lyophilized powder into the dialysis bag, and tie the other end of the dialysis bag.

[0060] Add 45 mL of release medium B to the dissolution bottle.

[0061] Place the dialysis bag in the dissolution bottle, and place the dissolution bottle in a constant temperature water bath shaker maintained at 37°C ± 0.5°C (this temperature is the normal temperature of the human body, and at this temperature the release behavior of the drug in the body can be better simulated). Make three parallel shakers at a speed of 75 rpm. From the time of sample placement, samples (release liquid) are taken from the dissolution bottle at 6h, 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 9d, 11d, 13d, 15d, 17d, 19d, 21d, 23d, 25d, 28d, 30d, 33d, 35d, and 37d, 2mL each time, and pass through a 0.22μm filter. At the same time, 2mL of fresh release medium B is added to the dissolution bottle each time.

[0062] 4. Perform HPLC test

[0063] (1) Chromatographic conditions

[0064] Chromatographic column: Agilent ZORBAX SB-C18, 4.6×150 mm, 5 μm.

[0065] Column temperature: 35°C.

[0066] Flow rate: 1.0mL / min.

[0067] Detection wavelength: 257nm.

[0068] Injection volume: 20 μL.

[0069] Mobile phase: 150 mL of 20 mmol / L potassium dihydrogen phosphate solution (take 1.3609 g of potassium dihydrogen phosphate solid, dilute to 10 ml with pure water, prepare a mother liquor with a concentration of 1 mol / L, filter and take 3 mL of the mother liquor, add it to 147 mL of Wahaha pure water) and mix with 350 mL of acetonitrile, adjust the pH to 7.4 with phosphoric acid, and degas for 20 minutes with ultrasound.

[0070] (2) Prepare the test solution

[0071] The samples (released liquid) obtained at different sampling time points were filtered through a 0.22 μm polyethersulfone filter membrane, and more than 0.5 mL of the filtrate was discarded (polyethersulfone filter membrane had no adsorption of aripiprazole), and the remaining filtrate was used as the test solution.

[0072] (3) Detection

[0073] The peak area of ​​the test solution was measured using a high performance liquid chromatography system. The results are shown in the following table:

[0074] Table 1 Peak area of ​​the test solution under 37℃ release conditions

[0075]

[0076]

[0077] 5. Calculate the release degree

[0078] The release amount at each time point was calculated by the external standard method using the peak area, and the release rate of aripiprazole long-acting dry suspension injection was calculated using the ratio of the cumulative release amount of the drug to the total amount of the drug, where the cumulative release amount of the drug was the drug release amount m of the nth sampling. n The release rate is calculated based on the sum of the drug release amounts taken out at each previous sampling according to the following formula:

[0079]

[0080] After calculation, the release rate of aripiprazole long-acting dry suspension injection at 37°C is as follows:

[0081] Table 2 Release of Aripiprazole Long-Acting Dry Suspension Injection (37°C)

[0082]

[0083]

[0084] Example 2

[0085] The method is basically the same as Example 1, except for the temperature of the constant temperature water bath shaker. Specifically, when simulating in vitro release, the dissolution bottle is placed in a constant temperature water bath shaker maintained at 38.5°C±0.5°C.

[0086] The peak area of ​​the test solution measured by high performance liquid chromatography system is shown in the following table:

[0087] Table 3 Peak area of ​​the test solution under the release condition of 38.5℃

[0088]

[0089] After calculation, the release rate of aripiprazole long-acting dry suspension injection at 38.5°C is as follows:

[0090] Table 4 Release of Aripiprazole Long-Acting Dry Suspension Injection (38.5°C)

[0091]

[0092]

[0093] Example 3

[0094] The method is basically the same as Example 1, except for the temperature of the constant temperature water bath shaker. Specifically, when simulating in vitro release, the dissolution bottle is placed in a constant temperature water bath shaker maintained at 40°C±0.5°C.

[0095] The peak area of ​​the test solution measured by the high performance liquid chromatography system is shown in the following table:

[0096] Table 5 Peak area of ​​the test solution under 40℃ release conditions

[0097]

[0098] After calculation, the release rate of aripiprazole long-acting dry suspension injection at 40°C is as follows:

[0099] Table 6 Release of Aripiprazole Long-Acting Dry Suspension Injection (40°C)

[0100] Sampling time Release rate (%) Sampling time Release rate (%) Sampling time Release rate (%) 6h 1.89 5d 78.48 11d 101.20 1d 14.35 6d 86.08 13d 103.14 2d 35.68 7d 90.72 15d 104.56 3d 53.59 8d 94.70 17d 104.46 4d 67.52 9d 98.31 19d 104.96

[0101] The time-release curves of the test product at 37°C, 38.5°C and 40°C were obtained by plotting the sampling time as the horizontal axis and the release rate as the vertical axis. Figure 4 .

[0102] Depend on Figure 4It can be seen that aripiprazole long-acting dry suspension injection can be completely released under the release conditions of 37°C, 38.5°C and 40°C, and the release speed is different. The release speed is faster under accelerated conditions (38.5°C and 40°C).

[0103] 2. Optimize the testing conditions

[0104] Before determining the aforementioned determination method of the present invention, we studied the concentration of the release medium B, the pH value of the release medium A, the volume fraction of Tween 80 and the pretreatment method of the release solution.

[0105] 1. Concentration of release medium B

[0106] In order to determine the release medium in the dissolution bottle, the equilibrium solubility of the lyophilized powder of aripiprazole long-acting dry suspension injection was determined using SDS aqueous solutions with concentrations of 1.0 g / L, 2.5 g / L, and 10.0 g / L, respectively.

[0107] (1) Preparation of release medium

[0108] 1.0g / L SDS aqueous solution: Accurately weigh 0.1g of SDS solid powder, dilute to 100mL with ultrapure water, and mix by ultrasonication.

[0109] 2.5 g / L SDS aqueous solution: Accurately weigh 0.25 g of SDS solid powder, dilute to 100 mL with ultrapure water, and mix by ultrasonication.

[0110] 10.0g / L SDS aqueous solution: Accurately weigh 1.0g of SDS solid powder, dilute to 100mL with ultrapure water, and mix by ultrasonication.

[0111] (2) Release and sampling

[0112] Take 5 mL of SDS aqueous solution with concentrations of 1.0 g / L, 2.5 g / L, and 10.0 g / L, respectively, and add them to 10 mL glass tubes, then add an excess of aripiprazole long-acting dry suspension injection lyophilized powder to the glass tubes, three in parallel, place the glass tubes in a constant temperature water bath shaker maintained at 37°C ± 0.5°C, take samples (release liquid) at intervals of 24 hours, filter through a 0.22 μm filter membrane, until the difference in the dissolved amount between the two intervals is less than 5%, it is considered that the equilibrium solubility is reached.

[0113] (3) HPLC determination

[0114] The peak area of ​​aripiprazole in the released solution was measured using the chromatographic conditions described in Example 1.

[0115] After calculation, the solubility of aripiprazole long-acting dry suspension injection at 37°C at different times is as follows:

[0116] Table 7 Solubility of Aripiprazole Long-Acting Dry Suspension Injection (37°C)

[0117]

[0118] From Table 7, we can see that:

[0119] (i) The solubility of aripiprazole in 1.0 g / L SDS aqueous solution is too low, and 1.0 g / L SDS aqueous solution is not suitable for use as a release medium;

[0120] (ii) The solubility of aripiprazole in 10.0 g / L SDS aqueous solution is too high. If 10.0 g / L SDS aqueous solution is used as the release medium, the volume of the release medium required in the release device (dissolution bottle) is small. Therefore, 10.0 g / L SDS aqueous solution is not suitable for use as the release medium.

[0121] (iii) The solubility of aripiprazole in 2.5 g / L SDS aqueous solution is 182.43 μg / mL, which meets the sink condition and the volume is suitable for the release device. Therefore, 2.5 g / L SDS aqueous solution is preferred as the release medium in the dissolution bottle.

[0122] In addition, the concentration of 2.5 g / L SDS aqueous solution has exceeded the critical micelle concentration of SDS and cannot pass through the dialysis bag, and the release medium B at this time has a solubilizing effect.

[0123] 2. pH value of release medium A and volume fraction of Tween 80

[0124] Six PBS buffers containing different volume fractions of Tween 80 and different pH values ​​were used as release media in dialysis bags, and 2.5 g / L SDS + 1.0 g / L sodium azide was used as release media in dissolution bottles to determine the release rate of aripiprazole long-acting dry suspension injection.

[0125] (1) Preparation of release medium in dialysis bag

[0126] Condition 1: Add 4 μL of Tween 80 (concentration of 0.2 ml / L, volume fraction of 0.02%) to 20 mL of 0.1 mol / L PBS buffer at pH = 6.4, mix by ultrasonication, and adjust the pH value to 6.4 with phosphoric acid.

[0127] Condition 2: Add 10 μL of Tween 80 (concentration of 0.5 ml / L, volume fraction of 0.05%) to 20 mL of 0.1 mol / L PBS buffer at pH = 6.4, mix by ultrasonication, and adjust the pH value to 6.4 with phosphoric acid.

[0128] Condition 3: Add 20 μL of Tween 80 (concentration of 1.0 ml / L, volume fraction of 0.1%) to 20 mL of 0.1 mol / L PBS buffer at pH = 6.4, mix by ultrasonication, and adjust the pH value to 6.4 with phosphoric acid.

[0129] Condition 4: 4 μL of Tween 80 (concentration of 0.2 ml / L, volume fraction of 0.02%) was added to 20 mL of 0.1 mol / L PBS buffer at pH = 7.4, and the mixture was mixed by ultrasonication.

[0130] Condition 5: Add 10 μL of Tween 80 (concentration of 0.5 ml / L, volume fraction of 0.05%) to 20 mL of 0.1 mol / L PBS buffer at pH = 7.4, and mix by ultrasonication.

[0131] Condition 6: Add 20 μL of Tween 80 (concentration of 1.0 ml / L, volume fraction of 0.10%) to 20 mL of 0.1 mol / L PBS buffer at pH = 7.4, and mix by ultrasonication.

[0132] (2) Prepare the release medium in the dissolution bottle

[0133] First weigh 2.5 g SDS and 1.0 g sodium azide, then dissolve them in a small amount of ultrapure water, mix and adjust the volume to 1 L, the concentration of SDS is 2.5 g / L, the concentration of sodium azide is 1.0 g / L, and finally degas by ultrasonication for 20 min.

[0134] (3) Release and sampling

[0135] Take 3.5 mg of lyophilized powder of aripiprazole long-acting dry suspension injection, accurately weigh and place it in dialysis bags containing 1 mL of the above six conditional release media respectively, tie the dialysis bags tightly and place them in a dissolution bottle of 45 mL 2.5 g / L SDS + 1.0 g / L sodium azide, place the dissolution bottle in a 37°C constant temperature water bath shaker with a rotation speed of 75 rpm, sample 2 mL at different times, filter with a 0.22 μm filter membrane to obtain the test solution.

[0136] (4) HPLC determination

[0137] The peak area of ​​aripiprazole in the released solution was measured using the chromatographic conditions described in Example 1.

[0138] After calculation, the release rates of aripiprazole long-acting dry suspension injection at different times under the release condition of 37°C are as follows:

[0139] Table 8 Release of aripiprazole long-acting dry suspension injection under 6 different conditions (37℃)

[0140]

[0141] The time-release curve of the test sample under different release medium A conditions was obtained by plotting the sampling time as the horizontal axis and the release degree as the vertical axis. Figure 3 .

[0142] Depend on Figure 3 It can be seen that:

[0143] (i) When the pH value of the release medium in the dialysis bag was 7.4, the release was too slow. When the volume fraction of Tween 80 was 0.02%, the release rate was 38.10% at the 17th day; when the volume fraction of Tween 80 was 0.05%, the release rate was 43.51% at the 17th day; when the volume fraction of Tween 80 was 0.10%, the release rate was 48.03% at the 17th day;

[0144] (ii) When the pH value of the release medium in the dialysis bag was 6.4, when the volume fraction of Tween 80 was 0.05% and 0.10%, the release was too fast, and the release degree reached more than 90% on the 7th day and 11th day, respectively. For the staged in vivo prediction, it may lead to insufficient discrimination of the method. When the volume fraction of Tween 80 was 0.02%, the release rate was moderate, which was most similar to the in vivo release result. Therefore, the release medium in condition 1 was preferred as the release medium in the dialysis bag.

[0145] 3. Pretreatment method of release liquid

[0146] Control group: The release liquid was centrifuged at 13000 rpm for 10 min and the supernatant was retained.

[0147] Experimental group: The release liquid was filtered through a 0.22 μm polyethersulfone (PES) membrane, and different volumes of filtrate were discarded to investigate whether the volume of the discarded filtrate had an effect on the sample measurement results.

[0148] The concentration of aripiprazole in the release solution after pretreatment was determined using the chromatographic conditions described in Example 1. The test results are shown in the following table:

[0149] Table 9 Effect of different pretreatment methods on the determination of aripiprazole concentration

[0150]

[0151] It can be seen from the above table that compared with high-speed centrifugation, when filtering the release liquid with a 0.22 μm polyethersulfone membrane, more than 0.5 mL of filtrate must be discarded so that the polyethersulfone membrane will not adsorb aripiprazole.

[0152] Therefore, when filtering the sample and taking the filtrate, the volume of the discarded filtrate must be greater than 0.5 mL.

[0153] 3. Release Methodology Validation

[0154] 1. Specificity of the determination method

[0155] The HPLC profiles of the test solution and blank release medium are shown in Figure 1 ,Depend on Figure 1 It can be seen that the blank release medium will not affect the determination of the test product.

[0156] 2. Linear relationship between concentration and peak area

[0157] Reference substance stock solution: Accurately weigh a certain amount of reference substance, add acetonitrile: water (7:3) to dissolve, and prepare 200 μg / mL reference substance stock solution.

[0158] Serial linear solutions: dilute the reference substance stock solution with release medium B to prepare a serial linear solution with a concentration level of 1 μg / mL to 60 μg / mL.

[0159] HPLC detection: The peak area corresponding to aripiprazole in the series of linear solutions was determined using the chromatographic conditions described in Example 1. The detection results are shown in the following table:

[0160] Table 10 Peak areas corresponding to aripiprazole in a series of linear solutions

[0161] serial number Concentration (μg / mL) Peak area average value 1 1 33.6、33.9、33.6 33.7 2 5 168.8、170.7、169.6 169.7 3 10 334.4、341.0、335.3 336.9 4 30 1000.8、1011.4、1004.7 1005.6 5 60 1981.8、2006.0、2003.7 1997.2

[0162] The concentration and peak area were linearly fitted to obtain the methodological validation linear graph of aripiprazole release, see Figure 2 .

[0163] Depend on Figure 2 It can be seen that when the concentration of aripiprazole is in the range of 1μg / mL to 60μg / mL, the concentration and peak area show a good linear relationship, and the linear equation is y=33.268x+3.3521, R 2 =1.0000(≥0.999).

[0164] 3. Precision, repeatability and stability

[0165] The peak area corresponding to aripiprazole in the solution was measured using the chromatographic conditions described in Example 1.

[0166] Precision and repeatability: The aripiprazole stock solution was diluted to obtain 10 μg / mL and 30 μg / mL aripiprazole standard solution samples, and the samples were injected 6 times.

[0167] Stability: The aripiprazole stock solution was diluted in parallel to obtain 12 samples of aripiprazole standard solution with a concentration of 10 μg / mL. After the preparation was completed, 6 samples were immediately injected and the remaining 6 samples were placed at room temperature for 48 hours before measurement.

[0168] The peak areas corresponding to aripiprazole in each dilution are as follows:

[0169] Table 11 Peak area corresponding to aripiprazole in each dilution

[0170]

[0171] It can be seen from the above table that the method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention has RSDs of precision and repeatability of 0.78% and 0.68% respectively, and RSD of stability of 0.92%. This method can meet the determination requirements.

[0172] 3. Comparison of release under 37°C and accelerated conditions

[0173] The release results of aripiprazole long-acting dry suspension injection at 38.5°C (Example 2, Table 4) and at 40°C (Example 3, Table 6) were fitted with the release results at 37°C (Example 1, Table 2). The fitting results are shown in Figure 5 .

[0174] Depend on Figure 5 It can be seen that the method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention not only provides an in vitro release rate determination method that can simulate more complex in vivo release conditions such as time-related release without changing the release mechanism, but also provides an accelerated experiment with a shortened cycle, and the experimental conditions can be selected according to different experimental requirements, providing a reliable and diversified choice.

[0175] 4. Correlation between in vitro and in vivo release

[0176] Aripiprazole long-acting dry suspension injection was administered once to healthy male New Zealand white rabbits at a dose of 18 mg / kg and an administration volume of 0.2 mL / kg.

[0177] Blood samples were collected at 2h, 6h, 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 10d, 12d, 14d, 16d, 18d, 21d, 24d, 31d, 35d, 38d, and 49d after administration, and the blood drug concentration was determined by LC-MS / MS to obtain the blood drug concentration-time curve.

[0178] The obtained blood drug concentration-time curve was processed by the area under the curve method (% AUC method) to obtain the cumulative release of aripiprazole long-acting dry suspension injection in New Zealand white rabbits. The results are shown in the following table:

[0179] Table 12 Blood drug concentration and cumulative release

[0180]

[0181]

[0182] The in vitro release curve in Example 1 was fitted with the in vivo cumulative release curve. The fitting results are shown in Figure 6 .

[0183] Depend on Figure 6 It can be seen that the in vitro release of the aripiprazole long-acting dry suspension injection obtained by the determination method provided by the present invention has a good correlation with the in vivo cumulative release (R 2 =0.99728).

[0184] This shows that the method for determining the release rate of aripiprazole long-acting dry suspension injection provided by the present invention is a mature method that can meet the quality control requirements.

Claims

1. A method for determining the release rate of aripiprazole long-acting dry suspension injection, characterized in that: The following steps are involved: Step 1: Add Tween 80 to 0.1 mol / L PBS buffer at pH 7.4, the concentration of Tween 80 is 0.2 ml / L, the pH value of the mixed solution is adjusted to 6.4, and ultrasonic degassing is performed to prepare release medium A; Step 2: Weigh SDS and sodium azide, dissolve them in a small amount of ultrapure water, mix them and make up to volume. The concentration of SDS is 2.5 g / L, and the concentration of sodium azide is 1.0 g / L. Degas by ultrasonication to prepare release medium B. Step 3: Add 1 mL of release medium A and 3.5 mg of aripiprazole long-acting dry suspension injection lyophilized powder to the dialysis bag, tie the dialysis bag tightly, add 45 mL of release medium B to the dissolution bottle, place the dialysis bag in the dissolution bottle, place the dissolution bottle in a constant temperature water bath shaker maintained at 37°C to 40°C, make three parallels, take samples from the dissolution bottle at different time points, and add an equal amount of fresh release medium B to the dissolution bottle; Step 4: Pass the samples obtained at different sampling time points through a 0.22 μm filter membrane to obtain a test solution, and use a high performance liquid chromatography system to determine the peak area of ​​the test solution; Step 5: The release amount at each time point is calculated by the peak area using the external standard method, and the release rate of aripiprazole long-acting dry suspension injection is calculated by the ratio of the cumulative release amount of the drug to the total amount of the drug.

2. The method for determining the release rate of aripiprazole long-acting dry suspension injection according to claim 1, characterized in that: It also includes the steps of pre-treating the dialysis bag, specifically: Cut the dialysis bag to an appropriate length, soak it in ultrapure water for 1 hour, then soak it in an ethanol-water solution for 20 minutes, with the volume ratio of ethanol to water being 2:8, and finally store it at 2℃~8℃ for later use.

3. The method for determining the release rate of aripiprazole long-acting dry suspension injection according to claim 1, characterized in that: In Step 3, the dialysis bag used is a 8kD to 14kD regenerated cellulose dialysis bag.

4. The method for determining the release rate of aripiprazole long-acting dry suspension injection according to claim 1, characterized in that: In Step 3, 2 mL of sample is taken each time and passed through a 0.22 μm filter.

5. The method for determining the release rate of aripiprazole long-acting dry suspension injection according to claim 1, characterized in that: In Step 4, the filter membrane is a polyethersulfone filter membrane, and more than 0.5 mL of the filtrate is discarded to obtain the test solution.

6. The method for determining the release rate of aripiprazole long-acting dry suspension injection according to claim 1, characterized in that: In Step 4, the chromatographic conditions of the high performance liquid chromatography system are as follows: Chromatographic column: Agilent ZORBAX SB-C18, 4.6×150 mm, 5 μm; Column temperature: 35°C; Flow rate: 1.0 mL / min; Detection wavelength: 257nm; Injection volume: 20 μL; Mobile phase: 150 mL of 20 mmol / L potassium dihydrogen phosphate solution was mixed with 350 mL of acetonitrile, the pH value was adjusted to 7.4 with phosphoric acid, and ultrasonic degassing was performed for 20 min.